Back to Journals » International Journal of Nanomedicine » Volume 20

Efficient Colon Cancer Immunogene Therapy Through Co-Delivery of IL-22BP mRNA and Tumor Cell Lysate by CLSV Nanoparticles [Retraction]

Authors Huang J, Wang K ORCID logo, Fu X ORCID logo, Zhu M, Chen X ORCID logo, Gao Y ORCID logo, Ma P ORCID logo, Duan X, Men K ORCID logo

Received 30 July 2025

Accepted for publication 30 July 2025

Published 6 August 2025 Volume 2025:20 Pages 9751—9752

DOI https://doi.org/10.2147/IJN.S557137



Huang J, Wang K, Fu X, et al. Int J Nanomedicine. 2023;18:8059—8075.

We, the Editors and Publisher of the International Journal of Nanomedicine, have retracted the published article.

Since publication, concerns have been raised by a third party about the integrity of the data in the article, including alleged image duplications in Figures 5 and 6 of the article. The authors then contacted the Journal requesting a correction of the article.

Following an investigation, the Journal and Publisher confirm that Figures 2, 5 and 6 include duplicated image panels which affect the integrity of the reported results. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.


This retraction relates to this paper


Creative Commons License © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.